Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial
This exploratory subgroup analysis found hydrocortisone plus fludrocortisone improved 90-day mortality in those with community acquired pneumonia (CAP) (39% v 51% placebo died; OR 0.60, 95% CI 0.43–0.83), with no evidence of a treatment effect in the non-CAP subgroup.
Source:
The Lancet Respiratory Medicine
SPS commentary:
The authors note that although a large proportion of patients with CAP also met criteria for acute respiratory distress syndrome (ARDS), the subgroup analysis was underpowered to fully discriminate between ARDS and CAP modifying effects on mortality reduction with corticosteroids.